Ph.D. Michael Exton - 12 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael Exton, Ph.D.
Issuer symbol
LXRX
Transactions as of
12 Feb 2026
Net transactions value
$0
Form type
4
Filing time
17 Feb 2026, 16:05:31 UTC
Previous filing
18 Feb 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Ph.D. Michael Exton filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 17 Feb 2026."

Quick Takeaways

  • This page summarizes Ph.D. Michael Exton's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Filing timestamp: 17 Feb 2026, 16:05.

What Changed

  • Previous filing in this sequence was filed on 18 Feb 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Exton Michael Chief Executive Officer, Director 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, THE WOODLANDS /s/ Michael Exton, Ph.D. 17 Feb 2026 0002029249

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Award $0 +862,440 $0.000000 862,440 12 Feb 2026 Common Stock 862,440 Direct F1, F2
transaction LXRX Stock Option (Right to Buy) Award $0 +1,293,670 $0.000000 1,293,670 12 Feb 2026 Common Stock 1,293,670 $1.37 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
F3 Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

Sponsored